Rotavirus vaccines

The mRNA sequence according to any one of the preceding claims, wherein the rotavirus is selected from the G-serotypes or P-serotypes G1 or G2 or G3 or G4 or G9 or G12 or P[4] or P[6] or P[8].

The mRNA sequence according to any one of the preceding claims, wherein the mRNA sequence encodes for at least one epitope of a protein, or of a fragment, variant or derivative thereof of a virus of the genus rotavirus, which is at least 60% identical, more preferably at least 70% identical, more preferably at least 80% identical, more preferably at least 90% identical, more preferably at least 95% identical, or most preferably at least 99% identical to the wild type protein or to the respective fragment of the wild type protein.

The mRNA sequence according to any one of the preceding claims, wherein the protein of a virus of the genus rotavirus is selected from a structural protein of rotavirus, preferably VP1 or VP2 or VP3 or VP4 or VP6 or VP7, or from a non-structural protein of rotavirus, preferably NSP1 or NSP2 or NSP3 or NSP4 or NSP5 or NSP6, more preferably VP2 or VP4 or VP6 or VP7 or NSP2 or NSP4.

The mRNA sequence according to any one of the preceding claims, wherein the mRNA sequence additionally comprises at least one sequence section encoding at least one helper peptide and optionally at least one sequence section encoding a peptide linker for enhancement of immunogenicity.

The mRNA sequence according to any one of the preceding claims, wherein the mRNA sequence additionally comprises at least one sequence section encoding at least one signal peptide.

The mRNA sequence according to any one of the preceding claims, wherein the coding region, encoding at least one epitope of a protein, or a fragment, variant or derivative thereof, of a virus of the genus rotavirus is mutated to delete at least one predicted or potential glycosylation site.

The mRNA sequence according to any one of the preceding claims, wherein the coding region, encoding at least one epitope of a protein, or a fragment, variant or derivative thereof, of a virus of the genus rotavirus is mutated to delete all predicted glycosylation sites.

The mRNA sequence according to any one of the preceding claims, wherein the mRNA sequence additionally comprises at least one sequence section encoding at least one transmembrane domain of a protein, or a fragment, variant or derivative thereof.

The mRNA sequence according to any one of the preceding claims, wherein the mRNA sequence additionally comprises at least one sequence section encoding at least one peptide or protein enabling VLP (virus like particle) formation.

The mRNA sequence according to any of the preceding claims, wherein the mRNA sequence comprises at least two coding regions, each encoding at least one epitope of a protein, or of a fragment, variant or derivative thereof of a virus of the genus rotavirus.

The mRNA sequence according to any one of the preceding claims, wherein the mRNA sequence comprises at least one sequence as shown in Tables 2, 4, 6, 8, 10-13, 15, 17, and 19.

The mRNA sequence according to any one of the preceding claims, wherein the G/C content of the coding region and/or coding sequence sections is increased compared with the G/C content of the coding region of the wild type mRNA, and wherein the coded amino acid sequence of said G/C-enriched mRNA is preferably not being modified compared with the coded amino acid sequence of the wild type mRNA.

The mRNA sequence according to any one of the preceding claims, wherein the mRNA sequence comprises additionally a 5′-UTR element and/or a 3′-UTR element and/or additionally at least one histone stem-loop sequence and/or additionally a 5′-CAP structure and/or a poly(A) sequence and/or a poly(C) sequence.

The mRNA sequence according to any one of the preceding claims, wherein the mRNA sequence is prepared for use as a vaccine.

Composition comprising one or more mRNA sequences as defined according to any one of the preceding claims and optionally a pharmaceutically acceptable carrier.